Alnylam (ALNY), Roche's Blood Pressure Drug Meets Study Goal

Alnylam Pharmaceuticals (ALNY) and partner Roche (RHHBY) announced positive results from the phase II KARDIA-2 study evaluating their investigational RNAi therapeutic zilebesiran in adults with hypertension (or high blood pressure).The KARDIA-2 study enrolled 672 adults with mild-to-moderate hypertension who were randomized to receive either a 600-mg dose of zilebesiran or placebo on top of one of three approved hypertension medications, namely olmesartan, amlodipine or indapamide.Study participants who rec ...